Blood-based Tests for Multicancer Early Detection (PATHFINDER): a Prospective Cohort Study

Overview

Journal Lancet

Publisher Elsevier

Specialty General Medicine

Date 2023 Oct 7

PMID 37805216

Authors

Deb Schrag

Tomasz M Beer

Charles H McDonnell 3rd

Lincoln Nadauld

Christina A Dilaveri

Robert Reid

Catherine R Marinac

Karen C Chung

Margarita Lopatin

Eric T Fung

Eric A Klein

Affiliations

Soon will be listed here.

Abstract

Background: Multicancer early detection (MCED) blood tests can detect a cancer signal from circulating cell-free DNA (cfDNA). PATHFINDER was a prospective cohort study investigating the feasibility of MCED testing for cancer screening.

Methods: In this prospective cohort study done in oncology and primary care outpatient clinics at seven US health networks, a convenience sample of adults aged 50 years or older without signs or symptoms of cancer consented to MCED testing. We collected blood, analysed cfDNA, and returned results to participants' doctors. If a methylation signature indicative of cancer was detected, predicted cancer signal origin(s) informed diagnostic assessment. The primary outcome was time to, and extent of, diagnostic testing required to confirm the presence or absence of cancer. This trial is registered at ClinicalTrials.gov, NCT04241796, and is completed.

Findings: Between Dec 12, 2019, and Dec 4, 2020, we recruited 6662 participants. 4204 (63·5%) of 6621 participants with analysable results were women, 2417 (36·5%) were men, and 6071 (91·7%) were White. A cancer signal was detected in 92 (1·4%) of 6621 participants with analysable results. 35 (38%) participants were diagnosed with cancer (true positives) and 57 (62%) had no cancer diagnosis (false positives). Excluding two participants whose diagnostic assessments began before MCED test results were reported, median time to diagnostic resolution was 79 days (IQR 37-219): 57 days (33-143) in true-positive and 162 days (44-248) in false-positive participants. Most participants had both laboratory tests (26 [79%] of 33 with true-positive results and 50 [88%] of 57 with false-positive results) and imaging (30 [91%] of 33 with true-positive results and 53 [93%] of 57 with false-positive results). Fewer procedures were done in participants with false-positive results (17 [30%] of 57) than true-positive results (27 [82%] of 33) and few had surgery (one with a false-positive result and three with a true-positive result).

Interpretation: This study supports the feasibility of MCED screening for cancer and underscores the need for further research investigating the test's clinical utility.

Funding: GRAIL.

Citing Articles

Implosion of Grail's Galleri Cancer Screening Test?.

Chatanaka M, Diamandis E EJIFCC. 2025; 36(1):7-8.

PMID: 40061064 PMC: 11886625.

Toward the use of nanopore RNA sequencing technologies in the clinic: challenges and opportunities.

Katopodi X, Begik O, Novoa E Nucleic Acids Res. 2025; 53(5).

PMID: 40057374 PMC: 11890063. DOI: 10.1093/nar/gkaf128.

Multicancer Detection (MCD) Testing in Gastrointestinal Cancers: An Evolving Tool for Early Diagnosis.

Ghosh A, Stephens K, Kandiah P, Hurt R, Gilman E Curr Gastroenterol Rep. 2025; 27(1):19.

PMID: 40047994 PMC: 11885400. DOI: 10.1007/s11894-025-00970-y.

Genomic and fragmentomic landscapes of cell-free DNA for early cancer detection.

Bruhm D, Vulpescu N, Foda Z, Phallen J, Scharpf R, Velculescu V Nat Rev Cancer. 2025; .

PMID: 40038442 DOI: 10.1038/s41568-025-00795-x.

Putting early cancer detection to the test.

Eisenstein M Nature. 2025; .

PMID: 39984691 DOI: 10.1038/d41586-025-00530-4.

References

Menon U, Gentry-Maharaj A, Hallett R, Ryan A, Burnell M, Sharma A . Sensitivity and specificity of multimodal and ultrasound screening for ovarian cancer, and stage distribution of detected cancers: results of the prevalence screen of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). Lancet Oncol. 2009; 10(4):327-40. DOI: 10.1016/S1470-2045(09)70026-9. View

Bredno J, Venn O, Chen X, Freese P, Ofman J . Circulating Tumor DNA Allele Fraction: A Candidate Biological Signal for Multicancer Early Detection Tests to Assess the Clinical Significance of Cancers. Am J Pathol. 2022; 192(10):1368-1378. DOI: 10.1016/j.ajpath.2022.07.007. View

Pinsky P, Gierada D, Black W, Munden R, Nath H, Aberle D . Performance of Lung-RADS in the National Lung Screening Trial: a retrospective assessment. Ann Intern Med. 2015; 162(7):485-91. PMC: 4705835. DOI: 10.7326/M14-2086. View

Bredno J, Lipson J, Venn O, Aravanis A, Jamshidi A . Clinical correlates of circulating cell-free DNA tumor fraction. PLoS One. 2021; 16(8):e0256436. PMC: 8386888. DOI: 10.1371/journal.pone.0256436. View

Neal R, Johnson P, Clarke C, Hamilton S, Zhang N, Kumar H . Cell-Free DNA-Based Multi-Cancer Early Detection Test in an Asymptomatic Screening Population (NHS-Galleri): Design of a Pragmatic, Prospective Randomised Controlled Trial. Cancers (Basel). 2022; 14(19). PMC: 9564213. DOI: 10.3390/cancers14194818. View

Krist A, Davidson K, Mangione C, Barry M, Cabana M, Caughey A . Screening for Lung Cancer: US Preventive Services Task Force Recommendation Statement. JAMA. 2021; 325(10):962-970. DOI: 10.1001/jama.2021.1117. View

Cristiano S, Leal A, Phallen J, Fiksel J, Adleff V, Bruhm D . Genome-wide cell-free DNA fragmentation in patients with cancer. Nature. 2019; 570(7761):385-389. PMC: 6774252. DOI: 10.1038/s41586-019-1272-6. View

Liu M, Oxnard G, Klein E, Swanton C, Seiden M . Sensitive and specific multi-cancer detection and localization using methylation signatures in cell-free DNA. Ann Oncol. 2021; 31(6):745-759. PMC: 8274402. DOI: 10.1016/j.annonc.2020.02.011. View

Hackshaw A, Clarke C, Hartman A . New genomic technologies for multi-cancer early detection: Rethinking the scope of cancer screening. Cancer Cell. 2022; 40(2):109-113. DOI: 10.1016/j.ccell.2022.01.012. View

10.

Lehman C, Arao R, Sprague B, Lee J, Buist D, Kerlikowske K . National Performance Benchmarks for Modern Screening Digital Mammography: Update from the Breast Cancer Surveillance Consortium. Radiology. 2016; 283(1):49-58. PMC: 5375631. DOI: 10.1148/radiol.2016161174. View

11.

Horeweg N, Scholten E, de Jong P, van der Aalst C, Weenink C, Lammers J . Detection of lung cancer through low-dose CT screening (NELSON): a prespecified analysis of screening test performance and interval cancers. Lancet Oncol. 2014; 15(12):1342-50. DOI: 10.1016/S1470-2045(14)70387-0. View

12.

Chamberlain J, Clifford R, Nathan B, Price J, BURN I . Repeated screening for breast cancer. J Epidemiol Community Health. 1984; 38(1):54-7. PMC: 1052316. DOI: 10.1136/jech.38.1.54. View

13.

Lennon A, Buchanan A, Kinde I, Warren A, Honushefsky A, Cohain A . Feasibility of blood testing combined with PET-CT to screen for cancer and guide intervention. Science. 2020; 369(6499). PMC: 7509949. DOI: 10.1126/science.abb9601. View

14.

Sprague B, Arao R, Miglioretti D, Henderson L, Buist D, Onega T . National Performance Benchmarks for Modern Diagnostic Digital Mammography: Update from the Breast Cancer Surveillance Consortium. Radiology. 2017; 283(1):59-69. PMC: 5375630. DOI: 10.1148/radiol.2017161519. View

15.

Bartlett E, Silva M, Callister M, Devaraj A . False-Negative Results in Lung Cancer Screening-Evidence and Controversies. J Thorac Oncol. 2021; 16(6):912-921. DOI: 10.1016/j.jtho.2021.01.1607. View

16.

Church T, Black W, Aberle D, Berg C, Clingan K, Duan F . Results of initial low-dose computed tomographic screening for lung cancer. N Engl J Med. 2013; 368(21):1980-91. PMC: 3762603. DOI: 10.1056/NEJMoa1209120. View

17.

Hackshaw A, Cohen S, Reichert H, Kansal A, Chung K, Ofman J . Estimating the population health impact of a multi-cancer early detection genomic blood test to complement existing screening in the US and UK. Br J Cancer. 2021; 125(10):1432-1442. PMC: 8575970. DOI: 10.1038/s41416-021-01498-4. View

18.

Klein E, Richards D, Cohn A, Tummala M, Lapham R, Cosgrove D . Clinical validation of a targeted methylation-based multi-cancer early detection test using an independent validation set. Ann Oncol. 2021; 32(9):1167-1177. DOI: 10.1016/j.annonc.2021.05.806. View

19.

Nadauld L, McDonnell 3rd C, Beer T, Liu M, Klein E, Hudnut A . The PATHFINDER Study: Assessment of the Implementation of an Investigational Multi-Cancer Early Detection Test into Clinical Practice. Cancers (Basel). 2021; 13(14). PMC: 8304888. DOI: 10.3390/cancers13143501. View

20.

Chen X, Dong Z, Hubbell E, Kurtzman K, Oxnard G, Venn O . Prognostic Significance of Blood-Based Multi-cancer Detection in Plasma Cell-Free DNA. Clin Cancer Res. 2021; 27(15):4221-4229. PMC: 9401481. DOI: 10.1158/1078-0432.CCR-21-0417. View